Q32 Bio reports mixed Phase 2a results: AA signal, AD miss

Q32 Bio Inc.

SIGNAL-AA: post-hoc analysis showed 16% mean SALT reduction vs 2% placebo at week 24 (p=0.045); 9% vs 0% achieved SALT-20.
SIGNAL-AD Part B failed primary endpoint: bempikibart 74% EASI improvement vs placebo 76% (not statistically significant).
Bempikibart safe and well tolerated in both trials; no SAEs or Grade 3+ related adverse events.
Company plans to enroll ~20 more patients in AA expansion; defers ADX-097 AAV Phase 2 trial to focus on bempikibart.
Biomarker data show robust Th2/Th1 reduction and 20-30% T-cell modulation, confirming target engagement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.